Profile

Pattern’s patented PPI-100 activates innate immunity against cancers and infectious diseases. Pattern intends commencing a clinical study in Q1 2026 in perioperative immunotherapy to address the ~40% relapse rate 5 years after cancer surgery. PPI-100 is a GMP version of an earlier product approved in ex-US jurisdictions for use against infectious diseases, where it proved safe & efficacious during widespread use. Pattern collaborates with Massachusetts General Hospital, MD Anderson, University of Toronto and McGill.

Pattern Pharma Inc. logo
patternpharma.com

Contact

Event details

Date: November 3 - 5, 2025

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences

Participants

22 in total
  • 20/20 OptimEyes Technologies Inc.
    20/20 OptimEyes Technologies has developed a mucoadhesive drug delivery platform technology that allows for…
  • BioBackers
    BioBackers is a nascent investor intelligence platform for therapeutics companies raising capital. The platform…
  • BioScript Solutions
    BioScript Solutions is a Canadian healthcare company committed to simplifying access to specialty care. It…
  • Bough Biosciences
    Bough Biosciences is a pre-seed stage biotech focused on the development of a therapy for treatment resistant…
  • HDAX Therapeutics
    HDAX Therapeutics, a biotechnology company pioneering a novel approach to target…
  • iCLASS Discovery
    iCLASS is a revolutionary TechBIO company merging multi-proteomics-centered data generation with next-generation…
  • Intrepid Labs Inc.
    Intrepid Labs revolutionizes drug formulation with Valiant™, an AI-driven robotic lab that explores…
  • JN Nova Pharma Inc.
    JN Nova Pharma is Canadian biotech company which has worked with National Research Council of Canada…
  • Noa Therapeutics
    Noa Therapeutics is pioneering a novel biased signal approach to AhR…
  • Pattern Pharma Inc.
    Pattern’s patented PPI-100 activates innate immunity against cancers…
  • PlantForm Corporation
    PlantForm Corporation is a biopharmaceutical company focused on the rapid development and production of specialty…
  • ProteinQure Inc.
    ProteinQure has built the best computational platform for designing peptides for extra-cellular targets. Its lead…
  • Q&C Services
    Q&C Services is Canada’s largest independent full-service consultant and importer for pharmaceutical, natural…
  • QurCan Therapeutics
    QurCan Therapeutics is advancing the next wave of genetic medicines for CNS…
  • Rhythm Biotherapeutics Inc.
    Rhythm Biotherapeutics develops first-in-class, heart-derived exosome therapeutics to prevent atrial fibrillation…
  • Singularity Pharma
    Singularity Pharma is a drug discovery business developing novel therapeutics for…
  • Specific Biologics
    Specific Biologics is developing Dualase®, an industry-leading genome editing platform with best-in-class…
  • Spiderwort Biotechnologies
    Spiderwort is a platform biomaterials company developing a suite of cellulose-based scaffolds for use in a number…
  • TheraVac Biologics
    TheraVac Biologics is a late-stage preclinical company developing innovative immunotherapies for…
  • Transpharmation
    Transpharmation is a contract research organisation led by scientists. Recognised by drug developers worldwide…
  • Virano Therapeutics
    Virano is a genetic immunomodulation company, developing next-generation combination products which reprogram the…
  • YYZ Pharmatech Inc.
    YYZ Pharmatech Inc. (“YYZ”) is a deep tech company endeavoring to profoundly progress new medicine…